A
ARS Pharmaceuticals, Inc. (SPRY)
NGM – Real Time Price. Currency in USD
8.54
+0.52 (6.48%)
At close: Jun 26, 2026, 4:00 PM EDT
8.80
+0.26 (3.04%)
After-hours: Jun 26, 2026, 7:44 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
8.54
+0.52 (6.48%)
At close: Jun 26, 2026, 4:00 PM EDT
8.80
+0.26 (3.04%)
After-hours: Jun 26, 2026, 7:44 PM EDT
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Robert Bell Ph.D. | Co-Founder & Chief Science Officer |
| Dr. Sarina Tanimoto M.B.A., M.D. | Co-Founder & Chief Medical Officer |
| Mr. Alexander A. Fitzpatrick Esq. | Chief Legal Officer & Secretary |
| Mr. Brian T. Dorsey M.S. | Chief Operating Officer |
| Mr. Daniel Relovsky | Senior Vice President of Marketing |
| Mr. Donn Casale | President |
| Mr. Justin Chakma | Chief Business Officer |
| Mr. Richard E. Lowenthal M.B.A., M.S., MSMSEL | Co-Founder, CEO & Director |
| Ms. Kathleen D. Scott CPA | Chief Financial Officer |
| Ms. Lynda Harris | Vice President of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-05-15 | 8-K | spry-20260515.htm |
| 2026-05-15 | 10-Q | spry-20260331.htm |
| 2026-05-13 | 8-K | d10320d8k.htm |
| 2026-04-29 | DEFA14A | spry_fy2026_defa14a.htm |
| 2026-04-29 | DEF 14A | spry-20260429.htm |
| 2026-04-29 | ARS | spry_fy2026_ars.pdf |
| 2026-03-09 | S-8 | spry-20260309.htm |
| 2026-03-09 | 8-K | spry-20260309.htm |
| 2025-11-10 | 8-K | spry-20251110.htm |
| 2025-11-10 | 10-Q | spry-20250930.htm |